For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com

Daiichi Sankyo Announces Booking Extraordinary Losses in its Non-consolidated Financial Results for Fiscal 2015 (Japanese GAAP)

Tokyo, Japan (April 28, 2015) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will book extraordinary losses in its non-consolidated financial results for fiscal 2015 (Japanese GAAP).

 

1. Details of extraordinary losses

(1)   Date of losses

April 21, 2015

(2)   Reason for losses

Daiichi Sankyo will record a loss on sales of investment securities due to the sale of its entire holding of Sun Pharmaceutical Industries Ltd. (hereafter, Sun Pharma) shares.

(Details of sale of Sun Pharma shares)

Shares sold: Ordinary shares of Sun Pharma,  214,969,058 shares

Carrying amount: \424.7 billion

Sale value: \378.4 billion

Sale date: April 21, 2015

(3)   Impact on financial results

Daiichi Sankyo will book a loss on sales of investment securities of ¥46.2 billion under extraordinary losses in its non-consolidated financial results for fiscal 2015(Japanese GAAP).

 

2. Impact on Consolidated Financial Results

There will be no impact on profit attributable to owners of the Company in consolidated financial results for fiscal 2015 (IFRS) as the loss of \45.8 billion will be recorded under “other comprehensive income” (as a financial asset at fair value).